Completed PHASE1 INTERVENTIONAL 5-arm NCT02655822

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of Ciforadenant as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Sponsor: Corvus Pharmaceuticals, Inc.

Conditions Metastatic Castration Resistant Prostate Cancer Renal Cell Cancer

Interventions Ciforadenant Ciforadenant + atezolizumab

Updated 21 times since 2017 Last updated: Aug 27, 2021 Started: Jan 31, 2016 Primary completion: Jun 30, 2021 Completion: Jul 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic Castration Resistant Prostate Cancer and Renal Cell Cancer and is currently completed. Corvus Pharmaceuticals, Inc. leads this study, which shows 21 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

21 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2021 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Mar 2021 — Sep 2021 [monthly]

Recruiting PHASE1
Feb 2021 — Mar 2021 [monthly]

Recruiting PHASE1

▶ Show 16 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE1
Dec 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Oct 2020 — Dec 2020 [monthly]

Recruiting PHASE1
Aug 2020 — Oct 2020 [monthly]

Recruiting PHASE1
Feb 2020 — Aug 2020 [monthly]

Recruiting PHASE1
Jan 2020 — Feb 2020 [monthly]

Recruiting PHASE1
Jun 2019 — Jan 2020 [monthly]

Recruiting PHASE1
Oct 2018 — Jun 2019 [monthly]

Recruiting PHASE1
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE1
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Jun 2018 — Aug 2018 [monthly]

Recruiting PHASE1
May 2018 — Jun 2018 [monthly]

Recruiting PHASE1
Feb 2018 — May 2018 [monthly]

Recruiting PHASE1
Aug 2017 — Feb 2018 [monthly]

Recruiting PHASE1
Feb 2017 — Aug 2017 [monthly]

Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE1

First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corvus Pharmaceuticals, Inc.
Genentech, Inc.

Data source: Corvus Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Boston, United States , Brisbane, Australia , Buffalo, United States , Chicago, United States , Clayton, Australia , Cleveland, United States , Detroit, United States , Edmonton, Canada , Miami, United States and 9 more locations